Trial intelligence / Profile preview

Selinexor maintenance after chemotherapy for advanced or recurrent endometrial cancer

2024-513167-68-00Phase 3Completed

Sponsor: Karyopharm Therapeutics Inc.
Start: Oct 2024
Modality: Small Molecules
Countries: 8

Overview

Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Selinexor maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Oct 2024; status: completed.

Drugs

selinexor

Conditions

endometrial cancer (EC)

Beyond the preview

Go deeper on 2024-513167-68-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-513167-68-00.